LianBio

Operating margin

—

Net margin

—

Return on equity

−42.4%

Return on assets

−34.5%

Return on capital (ROCE)

−42.3%

Liabilities / assets

8.2%

Debt / equity

0.10×

Book value / share

$2.42

Revenue growth (YoY)

—

Net income growth (YoY)

—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Altman Z″ (distress)

8.87safe

Accruals / assets

−3.5%clean

Piotroski F-Score

4/7mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

• Costs from exit or disposal · Delisting / listing-standard notice · Regulation FD disclosure · Other material eventFeb 13, 2024
• Entered a material agreement · Terminated a material agreementDec 26, 2023
• Director / officer change · Regulation FD disclosureDec 20, 2023
• Director / officer change · Regulation FD disclosureDec 19, 2023
• Regulation FD disclosureDec 6, 2023
• Other material eventDec 1, 2023
• Results of operationsNov 13, 2023
• Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Regulation FD disclosureOct 30, 2023

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.